

Sun Pharmaceutical Industries Ltd.,

FORM A

(as prescribed by SEBI under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992
[Regulation 13(1) and 13 (6)])

Regulation 13(1)- Details of acquisitions of 5% or more shares

Company Name : Sun Pharmaceutical Industries Ltd.,

Name, PAN No. & Address of shareholder with telephone number	Shareholding prior to acquisition	No. and percentage of shares/voting rights acquired	Date of receipt of allotment-advisee-Date of acquisition (specify)	Date of intimation to Company	Mode of acquisition (market/purchase/rights/preferential offer etc.)	Shareholding subsequent to acquisition	Trading member through whom the trade was executed with SEBI Registration No. of the TM	Exchange on which the trade was executed	Buy quantity	Buy Value
Name: Daiichi Sankyo Company Limited PAN No.:AACCD9196P Address: 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426, Japan Tel: +81-3-6225-1111	NIL	214,969,058 equity shares (representing 8.93% of the equity share capital of Sun Pharmaceutical Industries Limited)	16 th April, 2015, being the date of allotment of shares upon acquisition of shares pursuant to the effectiveness of amalgamation of Ranbaxy Laboratories Limited pursuant to the Scheme of Amalgamation of Ranbaxy Laboratories Limited with Sun Pharmaceutical Industries Limited, under Sections 391-394 of the Companies Act, 1956 ("Scheme").	16 th April, 2015	Pursuant to the Scheme	214,969,058 equity shares (representing 8.93% of the equity share capital of Sun Pharmaceutical Industries Limited.	N.A., as acquisition is pursuant to the Scheme	N.A., as acquisition is pursuant to the Scheme	N.A., as acquisition is pursuant to the Scheme	N.A., as acquisition is pursuant to the Scheme

For Sun Pharmaceutical Industries Ltd.,



Ashok Bhuta
Compliance Officer
Date: April 16, 2015

FORM A

**Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992
[Regulation 13(1)]**

Regulation 13(1) – Details of acquisition of 5% or more shares in Daiichi Sankyo Company, Limited

Name, PAN No. & address of shareholder with telephone number	Shareholding prior to acquisition	No. and percentage of shares /voting rights acquired	Date of receipt of allotment/advice of acquisition (specify)	Date of intimation to Company	Mode of acquisition (market purchase/public rights/preferential offer etc.)	Shareholding subsequent to acquisition	Trading Member through whom the trade was executed with SEBI Registration No. of the TM	Exchange on which the trade was executed	Buy quantity	Buy value
Daiichi Sankyo Company, Limited PAN No.:AACCD9196P Address: 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426, Japan Tel: +81-3-6225-1111	NIL	214,969,058 equity shares (representing 8.93% of the equity share capital of Sun Pharmaceutical Industries Limited)	16 th April, 2015, being the date of allotment of shares upon acquisition of shares pursuant to the effectiveness of amalgamation of Ranbaxy Laboratories Limited pursuant to the Scheme of Amalgamation of Ranbaxy Laboratories Limited with Sun Pharmaceutical Industries Limited, under Sections 391-394 of the Companies Act, 1956 ("Scheme").	16 th April, 2015	Pursuant to the Scheme	214,969,058 equity shares (representing 8.93% of the equity share capital of Sun Pharmaceutical Industries Limited)	N.A., as acquisition is pursuant to the Scheme	N.A., as acquisition is pursuant to the Scheme	N.A., as acquisition is pursuant to the Scheme	N.A., as acquisition is pursuant to the Scheme

For Daiichi Sankyo Company, Limited

Manabu Sakai

Manabu Sakai

Representative Director

Place: 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426, Japan

Date: 16th April, 2015